996 Shares in Becton, Dickinson and Company (NYSE:BDX) Bought by Legacy Solutions LLC

Legacy Solutions LLC bought a new position in Becton, Dickinson and Company (NYSE:BDX) during the 4th quarter, Holdings Channel reports. The fund bought 996 shares of the medical instruments supplier’s stock, valued at approximately $226,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Global Retirement Partners LLC boosted its stake in Becton, Dickinson and Company by 126.4% during the fourth quarter. Global Retirement Partners LLC now owns 6,008 shares of the medical instruments supplier’s stock worth $1,363,000 after buying an additional 3,354 shares in the last quarter. Northcape Wealth Management LLC lifted its holdings in shares of Becton, Dickinson and Company by 0.7% during the 4th quarter. Northcape Wealth Management LLC now owns 9,763 shares of the medical instruments supplier’s stock worth $2,215,000 after acquiring an additional 69 shares during the period. Bank of Jackson Hole Trust acquired a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at about $25,000. Lorne Steinberg Wealth Management Inc. increased its stake in Becton, Dickinson and Company by 12.8% in the fourth quarter. Lorne Steinberg Wealth Management Inc. now owns 27,693 shares of the medical instruments supplier’s stock valued at $6,283,000 after acquiring an additional 3,143 shares during the period. Finally, Mcdonald Partners LLC raised its position in Becton, Dickinson and Company by 11.0% in the fourth quarter. Mcdonald Partners LLC now owns 6,915 shares of the medical instruments supplier’s stock worth $1,569,000 after purchasing an additional 688 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analysts Set New Price Targets

BDX has been the topic of several analyst reports. Barclays upped their price objective on Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, February 12th. Finally, Piper Sandler boosted their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, January 28th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $278.29.

Insiders Place Their Bets

In other news, EVP David Shan sold 500 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total value of $120,000.00. Following the sale, the executive vice president now directly owns 5,741 shares in the company, valued at $1,377,840. The trade was a 8.01 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Bertram L. Scott sold 700 shares of the company’s stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total value of $159,593.00. Following the transaction, the director now directly owns 36,033 shares of the company’s stock, valued at $8,215,163.67. This represents a 1.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 10,544 shares of company stock worth $2,370,309 over the last ninety days. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Trading Up 0.1 %

BDX stock opened at $225.11 on Wednesday. The company has a quick ratio of 0.74, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $251.99. The company has a market cap of $64.64 billion, a P/E ratio of 37.39, a PEG ratio of 1.65 and a beta of 0.40. The business has a fifty day moving average of $232.72 and a 200-day moving average of $233.42.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. As a group, equities research analysts expect that Becton, Dickinson and Company will post 14.41 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be paid a $1.04 dividend. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 1.85%. Becton, Dickinson and Company’s payout ratio is 69.10%.

Becton, Dickinson and Company declared that its board has authorized a share repurchase program on Tuesday, January 28th that permits the company to buyback 10,000,000 shares. This buyback authorization permits the medical instruments supplier to buy shares of its stock through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.